BioSpace News Archive

Navidea Biopharmaceuticals, Inc. today announced it will host a conference call and webcast on Wednesday, March 23, 2022 at 5:00 p.m. (EDT) to discuss corporate developments and financial results.

Celcuity Inc. today announced that it will release its financial results for the fourth quarter and full year 2021 after the stock market close on Wednesday, March 23, 2022.

NLS Pharmaceutics Ltd. announces positive interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), in the treatment of narcolepsy.

Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRGTM rat (OncoRat®).

BetterLife Pharma Inc. is pleased to announce it has obtained the first set of positive in vivo pharmacokinetic data confirming the bioavailability of its lead compound BETR-001 in the brain and plasma of treated mice.

Johnson & Johnson MedTech* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, is adding two new innovations to its kinematically advanced and proven ATTUNE™ Knee portfolio: the ATTUNE™ Cementless Fixed Bearing Knee with AFFIXIUM™ 3DP Technology and the ATTUNE™ Medial Stabilized Knee System.

The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.

Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2021, provided key metrics around the ongoing commercial rollout of ANJESO® (meloxicam) injection, updated status of its neuromuscular blocking agent (NMB) portfolio, and provided other recent updates.

Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of its Uttroside B chemotherapeutic to treat liver cancer.

PolarityTE, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to sell 3,000.000435 shares of Series A convertible preferred stock.